Retina Implant AG Founder Professor Eberhart Zrenner and Research Team Honoured at EURETINA
EURETINA Presents the First Ever Innovation Award for Zrenner’s Subretinal Research Work
Retina Implant AG today announced that the Company’s founder Professor Eberhart Zrenner M.D. was awarded the second prize by The European Society for Retina Specialists (EURETINA). Professor Zrenner received the group’s inaugural Innovation Awards in London last week for his work in the field of artificial vision.
Dr. Zrenner, professor of Ophthalmology and director Emeritus of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tuebingen and the project team consisting of research teams from several universities, received the award for their investigations into subretinal implant technology.
Speaking of the award, Dr. Zrenner said: ‘It is an incredible honour that such a prestigious community of my peers has presented me with this award. We are proud of the work our team has done to restore useful vision to those suffering from retinitis pigmentosa.”
In 2003, Professor Zrenner and the leading project team managers founded Retina Implant AG , a leading developer of subretinal implants for the visually impaired. Zrenner and the team designed a 3 x 3 mm2 array containing 1,500 electrodes to stimulate the damaged cells using pulsed, light-dependent electrical stimuli. The team’s goal was to restore useful vision to the blind in order to provide these patients with some independence and to date clinical trials have produced positive results.
Retina Implant AG’s first clinical trial began in 2005 at the University Eye Clinic of Tuebingen, Germany by implanting 11 patients. Results of the first clinical trial have been presented at several industry-wide scientific meetings and were published in the journal Proceedings of the Royal Society B last November.
The 2011 EURETINA Innovation Award is a new initiative sponsored by EURETINA to support and encourage innovation in the field of retinal medicine. These awards aim to facilitate and support an entrepreneurial culture to deliver new market applications for the ultimate benefit of patients with retinal disorders, as well as engage and encourage the networking potential of the retinal community across the EU to improve both patient care and outcomes.
There were over 20 applications for the award and six finalists. As part of the short-listing process, nominees were invited to present their innovation at the EURETINA Congress. The winner was then selected by a judging panel chaired by Prof. Einar Stefansson of Landspitali University Hospital. The other finalists included Dr J Farrar (Trinity College) research into mutation-independent gene therapy for rhodo-spin linked autosomal dominant retinitis pigmentosa and Dr M Rudolf (University of Luebeck) and his team’s development of novel drug candidates for the prevention and treatment of age-related macular degeneration, which won the first prize.
###
Notes to Editor:
Photos available upon request
About Retina Implant AG
Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with private investors with the goal of developing the first fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005, and has started a second clinical trial this year. To learn more, visit: http://www.retina-implant.de/ .
About Professor Zrenner
Dr Zrenner is Professor of Ophthalmology and Director Emeritus of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tuebingen, Germany. His research interests include: retinal physiology and pathophysiology, neuroophthalmology, retina implants, electrophysiology and other methods of non-invasive function testing, neurodegeneration and ophthalmogenetics.
Dr Zrenner studied electronic engineering as well as medicine at the Technical University Munich, where he obtained his MD degree in 1972. Subsequently he worked within the Max-Planck-Society for 16 years and received a Fogarty fellowship at the national Eye Institute, Bethesda, MD (1977 and 1978), studying temporal, spatial and chromatic characteristics of retinal ganglion cells via extracellular recordings in monkey retina. After acquiring a Privatdozent (PD) degree he received an associated professorship at the University Eye Hospital in Munich. He became full professor and Medical Director of the University Eye Hospital in Tuebingen in 1989, now Center for Ophthalmology; he also served twice as Dean of the Medical Faculty of Tuebingen and also as Visiting Professor at the State University New York N.Y. USA.
Contact:
Schwartz Communications
Charlotte Webber / Amanda Hayhurst
+44
(0)208 090 4796
Retinaimplant@schwartzcomm.com
or
Retina
Implant AG
Dr. Walter-G. Wrobel
+ 49 7121 | 36403-111
Walter.Wrobel@retina-implant.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom